Moreover, drug resistance studies of USP39 in malignant tumors have not been mentioned in most malignant tumors, but only in a few malignant tumors, such as colorectal cancer, ovarian cancer, etc. The role of USP39 in anticancer drug resistance and the specific mechanism of action still need to be further explored. This evidence concerns the gene USP39 and colorectal cancer.